Insights

Innovative Antiviral Platform Atriva Therapeutics specializes in host-targeting antiviral therapies aimed at high unmet medical needs, presenting an opportunity for partners seeking cutting-edge treatments for respiratory diseases like COVID-19 and influenza.

Strong Financial Support With over CAD$57 million secured through investments from institutions including the European Investment Bank, the company is well-funded to advance clinical development and explore new collaborations.

Strategic Acquisitions The recent acquisition interest from Biocuretech indicates potential expansion opportunities and strategic partnerships for companies looking to enter or grow within the antiviral therapy space.

Active Clinical Development Atriva's lead candidate, ATR-002, has progressed into clinical trial phases, highlighting ongoing R&D activities and opportunities for partnering on clinical research, licensing, or distribution.

Growing Market Relevance As a member of initiatives like BEAT-COV, Atriva is positioned at the forefront of pandemic preparedness, offering opportunities to align with global health efforts and government-backed funding programs.

Atriva Therapeutics GmbH Tech Stack

Atriva Therapeutics GmbH uses 8 technology products and services including RSS, Joomla, jQuery Migrate, and more. Explore Atriva Therapeutics GmbH's tech stack below.

RSS

Content Management System

Joomla

Content Management System

jQuery Migrate

Javascript Libraries

jQuery

Javascript Libraries

X-XSS-Protection

Security

Plyr

Video Players

Nginx

Web Servers

Smush

Web Tools And Plugins

Atriva Therapeutics GmbH Email Formats	Example	Percentage
Last@atriva-therapeutics.com	Doe@atriva-therapeutics.com	50%
Last@atriva-therapeutics.com	Doe@atriva-therapeutics.com	50%

Atriva Therapeutics GmbH Email Formats

Example

Percentage

Last@atriva-therapeutics.com

Doe@atriva-therapeutics.com

50%

Last@atriva-therapeutics.com

Doe@atriva-therapeutics.com

50%

Frequently Asked Questions

Where is Atriva Therapeutics GmbH's headquarters located?

Atriva Therapeutics GmbH's main headquarters is located at Am Klopferspitz 19, Planegg/Martinsried, Bavaria 82152, DE. The company has employees across 2 continents, including EuropeAsia.

What is Atriva Therapeutics GmbH's official website and social media links?

Atriva Therapeutics GmbH's official website is atriva-therapeutics.com and has social profiles on LinkedIn Crunchbase.

What is Atriva Therapeutics GmbH's SIC code NAICS code?

Atriva Therapeutics GmbH's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Atriva Therapeutics GmbH have currently?

As of October 2025, Atriva Therapeutics GmbH has approximately 10 employees across 2 continents, including EuropeAsia. Key team members include Advisor To The Ceo: R. L.Site Manager, Svp Cmc: C. S.Director Preclinical Research: Y. F.. Explore Atriva Therapeutics GmbH's employee directory with LeadIQ.

What industry does Atriva Therapeutics GmbH belong to?

Atriva Therapeutics GmbH operates in the Biotechnology Research industry.

What technology does Atriva Therapeutics GmbH use?

Atriva Therapeutics GmbH's tech stack includes RSSJoomlajQuery MigratejQueryX-XSS-ProtectionPlyrNginxSmush.

What is Atriva Therapeutics GmbH's email format?

Atriva Therapeutics GmbH's email format typically follows the pattern of Last@atriva-therapeutics.com. Find more Atriva Therapeutics GmbH email formats with LeadIQ.

How much funding has Atriva Therapeutics GmbH raised to date?

As of October 2025, Atriva Therapeutics GmbH has raised $10M in funding. The last funding round occurred on Aug 12, 2020 for $10M.

When was Atriva Therapeutics GmbH founded?

Atriva Therapeutics GmbH was founded in 2015.

Atriva Therapeutics GmbH

Q: How many employees does Atriva Therapeutics GmbH have currently?

Atriva Therapeutics GmbH has approximately 10 employees.

Q: What technology does Atriva Therapeutics GmbH use?

Atriva Therapeutics GmbH's tech stack includes Open Graph, Plyr, jQuery Migrate, Neve, MySQL.

Biotechnology ResearchGermany2-10 Employees

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de
For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter (@AtrivaTx).

Insights

Similar companies to Atriva Therapeutics GmbH

Arbutus Biopharma Corporation